A groundbreaking study has pinpointed an immune cell signature that strongly forecasts death risk in idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung condition. Using single-cell RNA sequencing (scRNA-seq), researchers analyzed peripheral blood mononuclear cells (PBMCs), bronchoalveolar lavage (BAL) fluid, and lung tissue from over 1,000 individuals, including 555 IPF patients.
High-Risk Monocytes Linked to IPF Outcomes
The investigators identified a subset of monocytes labeled CD14+CD163−HLA-DRlow that carry a distinctive 230-gene expression signature associated with poorer outcomes. Patients with elevated levels of these monocytes exhibited markedly higher mortality, worse lung function as measured by forced vital capacity (FVC), and diminished expression of key T-cell co-stimulatory genes. Progression of IPF correlated with nearly double the proportion of these high-risk monocytes compared with stable disease.
These CD14+HLA-DRlow monocytes showed increased expression of pro-fibrotic, pro-angiogenic, and chemotactic factors, suggesting an active role in promoting lung scarring and disease advancement. The 230-gene signature also aligned with fibrosis-associated macrophage profiles in lung tissue, pointing to a broader network of immune dysfunction in IPF.
Remarkably, the researchers noted that existing drug classes might potentially reverse this high-risk signature. A refined six-gene panel retained strong predictive power across multiple cohorts, hinting at a path toward precision medicine interventions.
Toward Targeted Therapies
These results highlight the promise of immune-cell transcriptomic profiling to inform prognosis and treatment in IPF. By focusing on the pathways active in CD14+CD163−HLA-DRlow monocytes, clinicians may develop targeted therapies aimed at slowing or stopping disease progression. Future clinical trials will be needed to validate these targets and determine whether such interventions can improve survival for high-risk IPF patients.
Overall, this work marks a significant move toward personalized IPF management, giving clinicians a clearer sense of which patients are most at risk and how tailored therapies could alter outcomes.
Reference
Karampitsakos T et al. The transcriptome of CD14+CD163–HLA-DRlowmonocytes predicts mortality in idiopathic pulmonary fibrosis. Eur Respir J. 2025; DOI:10.1183/13993003.00804-2025.
Author:
Each article is made available under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
